Dimdazenil

Chemical compound

Rx in China

Identifiers

IUPAC name

7-Chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one

CAS Number

308239-86-3

PubChem CID

9885841

DrugBank

DB05721

ChemSpider

8061514

UNII

6J8AF7CLE4

Chemical and physical dataFormulaC₁₇H₁₇ClN₆O₂Molar mass372.81 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

Clc4cccc3n2cnc(c1nc(on1)CN(C)C)c2CN(C(=O)c34)C

InChI

InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
Key:JCYLWUVDHLVGER-UHFFFAOYSA-N

Dimdazenil (trade name Junoenil) is a pharmaceutical drug for insomnia.^[1] It is a benzodiazepine derivative and a partial positive allosteric modulator of the GABA_A receptor^[2] with two- to four-fold higher functional affinity for the α₁ subunit relative to the α₂, α₃, and α₅ subunits.

Medical use

Dimdezenil shows effectiveness in the treatment of insomnia, but has less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs;^[3] however, it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination.^[3] In China, dimdezenil is approved for short-term treatment of insomnia.^[4]

History

Dimdezenil was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia.^[3] By 2007, dimdezenil completed phase II clinical trials for this indication, with positive findings reported.^[5] In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.

References

^ Huang Z, Zhan S, Chen C, Zhang R, Zhou Y, He J, et al. (February 2024). "Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials". Sleep. 47 (2). doi:10.1093/sleep/zsad272. PMC 10851846. PMID 37875349.{{cite journal}}: CS1 maint: overridden setting (link)
^ Guilleminault C (2010). Sleep Medicine. Elsevier Health Sciences. pp. 574–. ISBN 978-1-4377-1836-2.
^ ^a ^b ^c Monti JM, Pandi-Perumal SR, Möhler H (28 September 2010). GABA and Sleep: Molecular, Functional and Clinical Aspects. Springer Science & Business Media. pp. 50–51. ISBN 978-3-0346-0226-6.
^ Syed YY (March 2024). "Dimdazenil: First Approval". Drugs. doi:10.1007/s40265-024-02020-9. PMID 38546956.
^ Plunkett JW (September 2007). Plunkett's Biotech & Genetics Industry Almanac 2008: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies. Plunkett Research, Ltd. pp. 311–. ISBN 978-1-59392-087-6.